Aspiriant LLC Portfolio holdings
Top Buys
| 1 |
Vanguard Small-Cap Value ETF
VBR
|
+$62.7M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$28.5M |
| 3 |
iShares Core S&P US Value ETF
IUSV
|
+$24.5M |
| 4 |
Apple
AAPL
|
+$10.3M |
| 5 |
iShares Core MSCI EAFE ETF
IEFA
|
+$7.7M |
Top Sells
| 1 |
iShares MSCI EAFE Min Vol Factor ETF
EFAV
|
+$3.08M |
| 2 |
iShares MSCI EAFE Value ETF
EFV
|
+$2.85M |
| 3 |
Berkshire Hathaway Class A
BRK.A
|
+$1.46M |
| 4 |
iShares MSCI Global Sustainable Development Goals ETF
SDG
|
+$1.26M |
| 5 |
iShares MSCI USA Min Vol Factor ETF
USMV
|
+$1.09M |
Sector Composition
| 1 | Technology | 4.09% |
| 2 | Financials | 2.48% |
| 3 | Communication Services | 1.07% |
| 4 | Healthcare | 0.71% |
| 5 | Consumer Discretionary | 0.62% |
Similar funds
Aspiriant LLC's Q1 2025 Portfolio in Review
As of Q1 2025, Aspiriant LLC held 308 positions worth $2.88B, up 4% from $2.77B the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Aspiriant LLC deployed $144M of net new capital in Q1 2025, opening 20 new positions and adding to 122 existing holdings. Its largest new stake was Trane Technologies: 4,004 shares worth $1.35M.
By sector, the portfolio is most concentrated in Technology at 4.1% of assets, down from 4.5% a quarter earlier, followed by Financials and Communication Services.
On the sell side, the largest reduction was iShares MSCI EAFE Min Vol Factor ETF, an estimated $3.08M trimmed.
- Aspiriant LLC's largest Q1 2025 buy was Trane Technologies: 4,004 shares worth $1.35M.
- Aspiriant LLC added most to Vanguard Small-Cap Value ETF in Q1 2025, an estimated $62.7M increase.
- Aspiriant LLC's biggest Q1 2025 reduction was iShares MSCI EAFE Min Vol Factor ETF, cutting an estimated $3.08M.
- Aspiriant LLC fully exited Loews in Q1 2025, selling an estimated $466K.
- Aspiriant LLC's ten largest holdings make up 68% of its $2.88B portfolio in Q1 2025.
- Aspiriant LLC opened 20 new positions and closed 20 in Q1 2025.
- Aspiriant LLC's portfolio value rose 4% quarter-over-quarter to $2.88B.
Based on Aspiriant LLC's 13F filing for Q1 2025, filed 21 Apr 2025.